<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">Liver metastasis</z:e> is a fatal step in the progression of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>); however, the epigenetic evolution of this process is largely unknown </plain></SENT>
<SENT sid="1" pm="."><plain>To decipher the epigenetic alterations during the development of <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastasis</z:e>, the DNA methylation status of 12 genes, including 5 classical CpG island methylator phenotype (CIMP) markers, was analyzed in 62 liver <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> and in 78 primary <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRCs</z:e> (53 stage I-III; 25 stage IV) </plain></SENT>
<SENT sid="2" pm="."><plain>Genome-wide methylation analysis was also performed in stage I-III <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRCs</z:e> and in paired primary and liver <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastatic cancers</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Methylation frequencies of MGMT and TIMP3 increased progressively from stage I-III <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRCs</z:e> to <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastasis</z:e> (P = 0.043 and P = 0.028, respectively) </plain></SENT>
<SENT sid="4" pm="."><plain>The CIMP-positive cases showed significantly earlier recurrence of disease than did CIMP-negative cases with <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastasis</z:e> (P = 0.030), whereas no such difference was found in stage I-III <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRCs</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>Genome-wide analysis revealed that more genes were methylated in stage I-III <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRCs</z:e> than in paired stage IV samples (P = 0.008) </plain></SENT>
<SENT sid="6" pm="."><plain>Hierarchical cluster analysis showed that stage I-III <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRCs</z:e> and stage IV <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRCs</z:e> were clustered into two distinct subgroups, whereas most paired primary and <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastatic cancers</z:e> showed similar methylation profiles </plain></SENT>
<SENT sid="7" pm="."><plain>This analysis revealed distinct methylation profiles between stage I-III <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRCs</z:e> and stage IV <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRCs</z:e>, which may reflect differences in epigenetic evolution during progression of the disease </plain></SENT>
<SENT sid="8" pm="."><plain>In addition, most methylation status in stage IV <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRCs</z:e> seems to be established before <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> </plain></SENT>
</text></document>